Staphylococcus aureus nasal carriage among the diabetic and non-diabetic haemodialysis patients

International Journal of Clinical Practice

Volumn 60, Issue 10, 2006, Pages 1204-1209

  Duran, Nizami ^a   Ocak, S ^a   Eskiocak, A F ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b Antakya Haemodialysis Center   (Turkey)

Author keywords

Haemodialysis; MRSA; Nasal carriage; Staphylococcus aureus; Susceptibility

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; INSULIN; METICILLIN; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CARRIER; BACTERIUM ISOLATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; FREQUENCY ANALYSIS; GENDER; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION;

CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; NOSE; RENAL DIALYSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33748522669     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2005.00789.x     Document Type: Article

References (36)

1. Kluytmans J, Belkum AV, Verbrugh H. Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10: 505-20.
2. Wenzel R, Pearl T. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995; 31: 13-24.
3. Toshkova K, Annemuller C, Lammler C. The significance of nasal carriage of Staphylococcus aureus as risk factor for human skin infections. FEMS Microbiol Lett 2001; 202: 17-24.
4. Ena J, Boelaert JR, Boyken LD, Van Landuyt HW, Godard CA, Herwaldt LA. Epidemiology of S. aureus infections in patients on hemodialysis. Infect Control Hosp Epidemiol 1994; 15: 78-81.
5. Goldblum SE, Ulrich JA, Goldman RS, Reed WP. Nasal and cutaneous flora among hemodialysis patients and personnel: Quantitative and qualitative characterization and patterns of Staphylococcal carnage. Am J Kidney Dis 1982; 2: 281-6.
6. Dobkin JF, Miller MH, Steigbigel NH. Septicemia in patients on chronic hemodialysis. Ann Intern Med 1978; 88: 28-33.
7. Chow JW, Yu VL. Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. Arch Intern Med 1989; 149: 1258-62.
8. Goldblum SE, Reed WP, Ulrich JZ. Staphylococcal carriage and infections in hemodialysis patients. Dial Transplant 1978; 7: 1140-63.
9. Zimakoff J, Bangsgaard Pedersen F, Bergen L et al. Staphylococcus aureus carriage and infections among patients in four haemo-and peritoneal-dialysis centres in Denmark. J Hosp Infect 1996; 33: 289-300.
10. Yu VL, Goetz A, Wagener M et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. New Engl J Med 1986; 315: 91-6.
11. Kirmani N, Tuazon CU, Murray HW et al. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med 1978; 138: 1657-9.
12. Tuazon CU, Perez A, Kishaba T, Sheagren JN. Staphylococcus aureus among insulin-injecting diabetic patients. An increased carrier rate. JAMA 1975; 24: 1272.
13. Berman DS, Schaefler S, Simberkoff MS, Rahal JJ. Staphylococcus aureus colonization in intravenous drug abusers, dialysis patients, and diabetics. J Infect Dis 1987; 155: 829-31.
14. Delamarie M, Mugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med 1997; 14: 29-34.
15. Gallacher SJ, Thomson G, Fraser WD, Fisher BM, Germmell CGM, AcCuish AC. Neutrophil bactericidal function in diabetes mellitus: Evidence for association with blood glucose control. Diabet Med 1995; 12: 916-90.
16. Kluytmans J, Mouton JW, Ijzerman EP et al. Nasal carriage of S. aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 1995; 171: 216-9.
17. Voss A, Doebbeling BN. The worldwide prevalence of methicillin-resistant S. aureus. Int J Antimicrob Agents 1995; 5: 101-6.
18. Ayliffe GAJ. The progressive intercontinental spread of methicillin resistant Staphylococcus aureus. Clin Infect Dis 1997; 24: S74-S79.
19. Boyce JM. Are the epidemiology and microbiology of methicillin resistant Staphylococcus aureus changing? JAMA 1998; 279: 623-4.
20. Cookson BD. Nosocomial antimicrobial resistance surveillance. J Hosp Infect 1999; 1: 97-103.
21. Holt JG, Krieg NR, Sneath PHA, Stanley JT, Williams TS. Bergey's Manual of Determinative Bacteriology, 9th edn. Baltimore, Maryland, USA: William and Wilkins, 1994; 532.
22. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 5th edn. NCCLS document M7-A5. Villanova, PA: 2000.
23. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002; 25: 5-8.
24. Scully BE, Briones F, Gu J-W, Neu HC. Mupiricon treatment of nasal staphylococcal colonization. Arch Intern Med 1992; 152: 353-6.
25. Goldblum SE, Ulrich JA, Goldman RS, Reed WP. Nasal and cutaneous Staphylococcus among patients receiving hemodialysis and attending personnel. J Infect Dis 1982; 145: 396.
26. Boelaert JR, De Baere YA, Geernaert MA et al. The use of nasal mupirocin ointment to prevent Staphylococcus aureus bacteraemias in haemodialysis patients: An analysis of cost-effectiveness. J Hosp Infect 1991; 19: 41-6.
27. Lamb YU. Overview of the role of mupirocin. J Hosp Infect 1991; 10: 27-38.
28. CDC. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997; 46: 626-35.
29. Herwaldt LA. Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients. J Hosp Infect 1998; 40: S13-23.
30. Piraino B, Perlmutter JA, Holley JL, Bernardini J. Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients. Perit Dial Int 1993; 13: S332-4.
31. Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: A decision analysis. Am J Kidney Dis 1996; 27: 687-94.
32. Vijayvargiya R, Veis JH. Antibiotic-resistant endocarditis in a hemodialysis patient. J Am Soc Nephrol 1996; 7: 536-42.
33. Boelaert JR. Staphylococcus aureus infection in haemodialysis patients. Mupirocin as a topical strategy against nasal carriage: A review. J Chemother 1994; 6: 19-24.
34. Boelaert JR, Van Landuyt HW, De Baere YA et al. Epidemiology and prevention of Staphylococcus aureus infections during hemodialysis. Nephrologie 1994; 15: 157-61.
35. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10: 505-20.
36. Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: Analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infection. Diabetes Metab 1992; 18: 187-201.